Tumor suppressor function of Rab25 in triple-negative breast cancer

被引:79
|
作者
Cheng, Ji-Ming [1 ,2 ]
Volk, Lisa [2 ,3 ]
Janaki, Deepak Kumar Mummidavarapu [4 ]
Vyakaranam, Sudhir [5 ]
Ran, Sophia [2 ,3 ]
Rao, Krishna A. [1 ,2 ,3 ]
机构
[1] So Illinois Univ, Sch Med, Div Hematol & Oncol, Dept Internal Med, Springfield, IL 62794 USA
[2] SimmonsCooper Canc Inst SIU, Springfield, IL USA
[3] So Illinois Univ, Sch Med, Dept Med Microbiol Immunol & Cell Biol, Springfield, IL 62794 USA
[4] Univ Illinois Coll Med Peoria, Dept Internal Med, Peoria, IL USA
[5] Univ Cincinnati, Div Nephrol, Cincinnati, OH USA
关键词
mammary neoplasia; Rab25; p21; RAS; tumorigenesis; apoptosis; ENDOTHELIAL GROWTH-FACTOR; FACTOR VEGF FAMILY; EXPRESSION; CELLS; SPECIFICITY; APOPTOSIS; PATHWAY; MEMBERS; OVARIAN;
D O I
10.1002/ijc.24900
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Rab proteins are a group of ubiquitously expressed proteins that are responsible for intracellular transport of vesicles. Recent evidence has shown that certain Rab proteins are involved in the pathogenesis of cancer. We have recently shown that Rab25 is lost in a large fraction of breast cancer samples, particularly those derived from hormonally insensitive tumors. We have further investigated the role of Rab25 by re-expressing Rab25 in tumorigenic cell lines and measuring the impact on tumor formation as well as on various molecular pathways through PCR array analysis. In vivo tumor growth of cell lines with re-expressed Rab25 was markedly suppressed. Our data suggest that Rab25 acts through multiple pathways to enhance apoptosis and to suppress angiogenesis and invasion by modulating VEGF-A and VEGFR-1 expression. These findings suggest that Rab25 represents a novel class of cellular modulators that can influence both tumor initiation and the progression of the established tumors, thus ultimately affecting the biology of the malignant disease.
引用
收藏
页码:2799 / 2812
页数:14
相关论文
共 50 条
  • [21] ZBTB7A is a tumor suppressor and novel therapeutic target in triple-negative breast cancer
    Molloy, Mary Ellen
    Lewinska, Monika
    Liu, Xue-Song
    Wang, Angela A.
    Yuan, Zhi-Min
    CANCER RESEARCH, 2016, 76
  • [22] Tumor microenvironment and immunotherapy for triple-negative breast cancer
    Guo, Zijie
    Zhu, Ziyu
    Lin, Xixi
    Wang, Shenkangle
    Wen, Yihong
    Wang, Linbo
    Zhi, Lili
    Zhou, Jichun
    BIOMARKER RESEARCH, 2024, 12 (01)
  • [23] Triple-Negative Breast Cancer: Tumor Immunogenicity and Beyond
    Ibrahim, Elio
    Diab, Ernest
    Hayek, Rony
    Hoyek, Karim
    Kourie, Hampig
    INTERNATIONAL JOURNAL OF BREAST CANCER, 2024, 2024
  • [24] Therapeutic implications of rab25 loss on breast cancer pathogenesis
    Cheng, JiMing
    Sunkara, Bharath
    Rao, Krishna
    CANCER RESEARCH, 2009, 69
  • [25] Metastasis suppressor 1 acts as a tumor suppressor by inhibiting epithelial-to-mesenchymal transition in triple-negative breast cancer
    Yu, Jinling
    Shen, Weida
    Gao, Beimin
    Xu, Jinping
    Gong, Bo
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2020, 35 (01): : 74 - 81
  • [26] Rab25 in cancer: a brief update
    Mitra, Shreya
    Cheng, Kwai W.
    Mills, Gordon B.
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2012, 40 : 1404 - 1408
  • [27] Rab25 and RCP in cancer progression
    Kyung Hwa Cho
    Hoi Young Lee
    Archives of Pharmacal Research, 2019, 42 : 101 - 112
  • [28] Triple-Negative Breast Cancer
    Winkeljohn, Debra L.
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2008, 12 (06) : 861 - 863
  • [29] Triple-Negative Breast Cancer
    Hudis, Clifford A.
    CANCER JOURNAL, 2010, 16 (01): : 10 - 11
  • [30] Rab25 and RCP in cancer progression
    Cho, Kyung Hwa
    Lee, Hoi Young
    ARCHIVES OF PHARMACAL RESEARCH, 2019, 42 (02) : 101 - 112